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Introduction
Mastalgia, or breast pain (or mastodynia), is globally a com-
mon symptom experienced by women of reproductive age; 
the reported prevalence ranges from 41% to 79%.1–3 Data re-
ported in this narrative review were obtained from random-
ized controlled trials, observational studies, and review ar-
ticles through PubMed, PubMed Central, HINARI, Google 
Scholar, and Medline Internet searches, with an emphasis on 
studies published in the last 2 decades. The terms searched 
included “mastalgia”, “mastodynia”, “breast pain”, “cyclic 
mastalgia” and “noncyclic mastalgia”.
Mastalgia is typically approached according to its classi-
fication, of which there are three types:
1. Cyclic mastalgia – Cyclic breast pain occurs 1 
to 2 weeks before, and is relieved by, the onset of 
menstruation. The pain is generally diffuse and 
bilateral though it may be more severe on 1 side 
than the other and radiate to the upper arm and 
axilla. The pain is often described as sharp, shoot-
ing, stabbing, heavy, aching, deep tenderness, or 
throbbing. Patients are usually in their fourth or 
fifth decade of life. Cyclic mastalgia may resolve 
spontaneously in up to 22% of cases, or resolution 
may occur with a hormonal event, such as preg-
nancy or menopause. The condition may persist 
in up to 65% of cases after treatment, and the suf-
fering may continue until the onset of menopause.
  It has been stressed that cyclical mastalgia, al-
though associated with the menstrual cycle, is not 
merely premenstrual syndrome (PMS) but is a 
separate entity with a different presentation, aeti-
ology, and effective treatment and although mas-
talgia is a well-documented symptom of PMS, it 
is possible for cyclic mastalgia to occur outside of 
the context of PMS.4
2. Noncyclic mastalgia – The breast pain bears no 
relation to menses. It is usually unilateral, local-
ized to a particular quadrant of the breast, and 
may be constant or intermittent. Patients are 
usually older and are often perimenopausal. Pain 
tends to be well localized and often subareolar or 
medial; it may also be bilateral and is often de-
scribed as heavy, aching, tender, burning, pulling, 
stabbing, or pinching.
  Various lesions can cause noncyclical mastal-
gia, a classification that includes cysts, periductal 
mastitis, stretching of Cooper’s ligaments, trau-
matic fat necrosis, Mondor’s disease, diabetic 
mastopathy, and even neoplasia.4 Some women 
have a localized tender area—the trigger spot—in 
the affected breast. Noncyclic mastalgia can re-
solve without treatment in up to 50% of cases, but 
can it also be more challenging to treat and needs 
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sufficient evaluation to define the causative factor 
and to rule out neoplasia.5,6
3. Extramammary (nonbreast) pain – Extramam-
mary pain arises from structures other than the 
breast but mimics breast pain. Patients can belong 
to any age group. The origin of pain includes the 
chest wall or outside the chest wall. Common 
chest wall conditions include costochondritis 
(chondropathia tuberosa, Tietze syndrome), re-
ferred nerve root pain from spinal compression 
or spondylosis, surgical trauma, and herpes zos-
ter. Other conditions causing extramammary 
breast pain include diverse causes, such as isch-
emic heart disease, biliary pain, oesophagitis, and 
peptic ulcer disease. The pain is almost always 
unilateral.  
Ader and Shriver, in 1997,7 reported the results of a de-
scriptive study of 231 women under 55 years of age who vis-
ited a single breast clinic. They found that 30% of premen-
strual women suffered from cyclic mastalgia lasting for 5 
days or more in a month, and the “clinical” level of mastalgia 
interfered with usual sexual activity for 33%, with physical 
activity for 29%, with social activity for 15%, and with work 
for 15% of the women. The study further found that young 
women (≤ 35 years old) were more than three times as likely 
to have had a mammogram (75%) if they regularly experi-
enced cyclic mastalgia than if they did not (24%; P < 0.05) 
thereby putting pressure on the healthcare system. Hence, 
the authors suggested that mastalgia should not be ignored 
but subjected to further biopsychosocial investigation. 
Scurr et al., in 2014,8 presented the results of a global study 
that examined the prevalence, severity, and impact of breast 
pain among 1659 females (mean age 34.1 ± 13.2 years). The 
study found that over half of the sample (51.5%) experienced 
breast pain with a severity similar to that reported in clinical 
populations. Of the symptomatic participants, 41% and 35% 
reported breast pain affecting the quality of life measures of 
sex and sleep, respectively. Moreover, 10% of symptomatic 
participants had suffered breast pain for over half their lives. 
The results of this study proved that mastalgia is a significant 
health-related issue within the general population. The same 
study showed that there was a higher prevalence of breast 
pain in older participants, larger-breasted participants, and 
those who were less fit and active. The reported relationship 
between breast pain and fitness and activity levels may offer 
an alternative treatment in the form of exercise intervention 
strategies to reduce breast pain.
Brown et al.9 conducted a study to evaluate breast pain 
among female runners who participated in the 2012 London 
Marathon. They found that mastalgia was present in one-
third of the 1285 participants and about 56% of the sufferers 
required medication.
Aetiology of mastalgia
The aetiology of mastalgia is not clearly understood. Hor-
monal assays of oestrogen, progesterone, and prolactin have 
shown inconsistent abnormalities despite the relationship of 
the cyclic variant to the menstrual cycle. The major aetiolog-
ical factors mentioned in the literature include:
Endocrine abnormalities
Two main theories have emerged regarding the aetiology of 
mastalgia: 
1. Oestrogen – Increased oestrogen secretion and 
deficient progesterone production during the lu-
teal phase of the menstrual cycle leading to hor-
monal imbalance.
  The studies of serum hormones levels do not 
support the hormone imbalance theory, as hor-
monal levels were found to be similar in patients 
and controls in earlier studies conducted by Ma-
larkey et al.,10 though Sitruk et al.11 showed a sig-
nificantly depressed level of luteal progesterone, 
thus supporting the hormone imbalance theory. 
2. Hyperprolactinaemia – Peters et al. found that 
patients with mastalgia had significantly high-
er levels of prolactin compared with controls.12 
Kumar et al. tested pituitary function in benign 
breast disorders and found a significant abnor-
mality in patients with severe cyclic mastalgia 
(P < 0.05), but not in those with noncyclic mastal-
gia.13 No abnormalities of thyroid function were 
found. Another study by Kumar et al. indicated 
that dynamic tests of prolactin released in cyclic 
mastalgia may be useful in predicting a subse-
quent satisfactory response to endocrine therapy.14
Water retention
A traditional view has been that there is a premenstrual 
increase in total body water and that this causes mastalgia. 
However, an impressive study was undertaken by Preece et 
al., at the Cardiff Mastalgia Clinic,15 in which total body wa-
ter (TBW) was measured early and late in the menstrual cy-
cles of 56 women, 39 of whom had breast pain. It was found 
that in some cases TBW actually decreased, while in others 
there was no change from the early cycle measurement. No 
TBW pattern correlated with any syndrome of breast pain or 
with any psychoneurotic profile.
Psychoneurosis
Multiple studies have demonstrated an association between 
mastalgia, particularly the treatment-resistant variant, and 
various psychological symptoms, such as depression, anxi-
ety, history of emotional abuse, and somatization.16–17 
Johnson et al., after studying the pattern of mastalgia in 
female veterans, hypothesized that, like somatization, fre-
quent mastalgia may also be associated with psychiatric con-
ditions and may cluster with unexplained pain syndromes.18
Miscellaneous factors 
Caffeine and methylxanthines 
Caffeine is frequently listed as a causal factor for mastalgia, 
and Ader et al.1 and Eren et al.19 both found a significant 
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association (P < 0.05) between caffeine consumption and 
breast pain in their studies. Minton and Abou-Issa, in 1989, 
published the summarized results of 15 years of clinical and 
laboratory studies that had been undertaken to search for 
a biochemical basis for the development and resolution of 
symptomatic benign fibrocystic disease. They found that 
caffeine restriction produced significant improvement in the 
symptoms of many women.20 It has been suggested that over-
stimulation of breast cells may occur due to interference with 
adenosine triphosphate degradation by methylxanthines 
present in tea, coffee, cola, and chocolate; however, Millet 
and Dirbas did not find any significant benefit following the 
exclusion of such items from the diet of mastalgia patients.21
Smoking
Smoking has been attributed to increased breast pain by in-
creasing epinephrine levels in the breast.  Eren et al. found 
a statistically significant association (P < 0.05) between ciga-
rette smoking and mastalgia.19 Ader et al. found that smok-
ing was associated with mastalgia (odds ratio = 1.52).7 
Aberration in lipid metabolism
Multiple therapeutic and investigative studies have been 
published that suggest the possibility of the role of lipid pro-
file aberrations in the pathophysiology of mastalgia in gener-
al and cyclic mastalgia in particular. Sharma et al. conducted 
a prospective study with the aim of looking for such aberra-
tions.22 They enrolled 57 patients who had been symptomatic 
for at least 6 months before presentation, and a detailed se-
rum lipid profile workup was performed on days 1, 15, and 
25 of their menstrual cycles. The patients with symptoms of 
maximal severity during (or limited to) the luteal phase of 
the menstrual cycle were included in group I (n = 32), where-
as those who had mastalgia but no cyclical variation were 
included in group II (n = 25). The subjects in group II were 
treated as controls. At day 25, there was an elevation in mean 
values of high-density lipoproteins cholesterol (HDL-C) 
(P = 0.03) and the HDL-C/low-density lipoproteins choles-
terol (LDL-C) ratio (P = 0.01). There was also a reduction in 
the total cholesterol (TC)/HDL-C ratio (P < 0.03) in group 
I and no such changes were observed in group II patients. 
Furthermore, when the mastalgia patients were treated with 
a low-fat dietary regimen, there was a significant difference 
in the responses of these 2 groups (P < 0.0001). The authors 
concluded that cyclic mastalgia is an entity that is distinctly 
different from noncyclic mastalgia and has links to lipid me-
tabolism aberrations. 
The breast tissue of women with mastalgia is believed 
by some to be high in saturated fatty acids and deficient in 
gamma-linolenic acid (GLA), which renders it abnormally 
sensitive to normal hormone levels, thus resulting in pain.23 
With prolonged high-dose treatment (320 mg/day for 3 to 
6 months), the GLA content of evening primrose oil (EPO) 
restores the balance of fatty acids in the breast tissue, with 
high efficacy and few side effects.23
Mastalgia and breast cancer
There may be an association between mastalgia and the sub-
sequent development of breast cancer, but the nature of the 
relationship is not clear based on current evidence. Some 
researchers have questioned whether breast pain is truly 
related to cancer or whether this pain prompts an evalua-
tion in which an otherwise asymptomatic cancer is identi-
fied.24 It is very rare to have mastalgia as the only symptom 
of breast cancer, though breast pain has been reported along 
with other symptoms of breast cancer in the range of 5% to 
18% of cases of breast cancers. Cochrane et al. conducted a 
retrospective study of 2332 new patients attending a breast 
clinic in South Wales and found that only 1 cancer presented 
with mastalgia alone.25 Plu-Bureau et al. conducted a case–
control study of 420 premenopausal women matched for age 
and age at first full-term pregnancy and found that a histo-
ry of cyclic mastalgia was associated with an increased risk 
of breast cancer.26 Another study conducted by Goodwin et 
al. included 192 premenopausal women recently diagnosed 
with node-negative breast cancer who were age-matched 
with 192 controls, and the results pointed towards an asso-
ciation between cyclic breast tenderness with breast cancer 
risk in premenopausal women.27 Khan and Apkarian studied 
the association between mastalgia and breast cancer by an-
alysing data for 5463 women who attended the Breast Care 
Center of University Hospital, Syracuse, New York, and after 
making adjustments for various risk factors (early menarche, 
late first birth, late menopause, exogenous hormone use, and 
positive family history), it was found that women who expe-
rienced pain were less likely to be diagnosed with breast can-
cer.28 Conversely, a study by Preece et al. found that 36 of 240 
women with newly diagnosed breast cancer had localized 
breast pain as a presenting symptom. Of these, 10 women 
(28%) had normal mammographic findings and were later 
diagnosed as having subclinical breast cancer at the site of 
pain after further evaluation.29 Therefore, cancer must be 
seriously considered as a differential diagnosis in patients 
presenting with well-localized breast pain. These patients 
should be followed up on for at least 1 year after the onset of 
the pain before cancer is confidently excluded.29,30
Histologic associations
Studies undertaken for identification of underlying histo-
pathological diagnoses in mastalgia patients have shown an 
inconsistent association of breast pain with fibrocystic his-
tology. In a study conducted by Watt-Boolsen et al., the fi-
brocystic histologic findings of intraductal proliferation, ad-
enosis, sclerosing adenosis, duct ectasia, intraductal debris, 
papillomatosis, apocrine metaplasia, microcysts, and prolif-
erative periductal connective tissue were common but with-
out any statistically significant difference among groups with 
cyclic breast pain, noncyclic pain, and no symptoms.31 In a 
study involving 39 women with cyclic breast pain who un-
derwent breast biopsy, Jorgensen and Watt-Boolsen32 found 
that all had fibrocystic histologic changes. However, a similar 
set of changes were also present in 61 of 68 women without 
breast pain who underwent biopsy for other reasons. Addi-
tionally, it has been established by various other studies33–35 
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that, except for proliferative changes or cellular atypia, histo-
logic changes do not confer an increased risk of breast cancer 
and that these histologic findings are to be considered part of 
the spectrum of normal involution in the breast. Ramakrish-
nan et al. studied the potential role of inflammation and 
inflammatory cytokines in mastalgia and found that there 
was no difference between 29 premenopausal women with 
breast pain and 29 matched asymptomatic women regarding 
the degree of inflammatory cell infiltration and cytokine (in-
terleukin 6 and tumour necrosis factor-alpha) expression in 
breast tissue specimens.36
Clinical assessment and investigations
Clinical assessment of mastalgia cases includes a detailed 
history to determine the nature, severity, timing, and dura-
tion of the pain. The relationship of pain to the menstrual 
cycle and its impact on work and routine activities are im-
portant. History must include relevant questions to stratify 
the patient’s risk of breast cancer, such as the family history 
and oestrogen window. After history building, there should 
be a careful examination of the breasts and axillae. Particular 
attention should be paid to extramammary causes of breast 
pain and specifically the possibility of costochondral pain, in 
the case of noncyclic mastalgia. 
Investigations in cases presenting with mastalgia are un-
dertaken with the aim of screening for breast cancer. Though 
mastalgia is not a common presenting symptom of breast 
cancer, it does present an opportunity for screening for an 
otherwise common cancer, particularly in regions where 
there is generally poor access to dedicated breast care cen-
tres.  
Radiologic investigation is, however, not indicated in 
young women with no risk factors and normal breast exam-
ination findings. Mammography is recommended for wom-
en over 35, those with a positive family history, and patients 
with noncyclic mastalgia. Ultrasound examination is helpful 
if there is a clinically palpable lesion or if the patient pres-
ents with localized noncyclic pain. The negative predictive 
value of a proper clinical examination, combined with mam-
mography or ultrasound, approaches 100%.37 If the physical 
examination or radiology identifies an abnormality, such as 
a breast lump, this must be thoroughly investigated to com-
plete the standard “triple assessment”.6 
Breast pain assessment 
Assessment and quantification of breast pain may be difficult 
due to the wide variability.24 Pain may wax and wane without 
any provocation, with specific activities, or with the men-
strual cycle. Assessment with the use of common pain-rating 
instruments, such as a visual analogue scale (VAS) or numer-
ical rating scale (NRS), may be helpful in evaluating breast 
pain, for making decisions regarding treatment, and for 
monitoring responses to therapy.  Daily breast pain diaries 
have been found to be useful in management after prospec-
tive documentation of the occurrence and severity of pain, 
aggravating and alleviating factors, use of medications, and 
interference with lifestyle.4,6 These diaries are more accurate 
and complete than mere recall of symptoms by patients.6 In a 
study by Khan and Apkarian, a modified version of the Mc-
Gill Pain Questionnaire (SF-MPQ) was administered to 271 
women with cyclic or noncyclic breast pain, and the mean 
pain rating index was found to be 12.0 out of 45; similar to 
pain ratings in cases of rheumatoid arthritis and cancer.38
Management of mastalgia 
The management of mastalgia can be broadly divided 
into nonpharmacological interventions and pharmacologic 
interventions.
Nonpharmacologic and alternative 
interventions
Nonpharmacologic interventions have frequently been 
found to improve mastalgia in clinical practice39 and are of 
low risk and expense to the patient, although there have been 
fewer scientific studies into the effectiveness of these inter-
ventions.
Reassurance  
Reassurance, re-evaluation, and proper explanation of the 
condition have vital roles in the treatment of women with 
mastalgia.40 Barros et al. conducted a study on 121 women 
suffering from mastalgia to evaluate the results of the ap-
plication of a nonpharmacologic treatment based on expla-
nation and reassurance.41 The subjects received reassurance 
and information and were followed up with a questionnaire 
2–3 months later, and comparison of pain parameters of the 
patients before and after reassurance was made. The authors 
reported a success rate of 70.2% (n = 85) with reassurance. 
Upon evaluation of subjective pain intensity reporting, re-
assurance was effective in 85.7% of the patients with a mild 
form of mastalgia, in 70.8% with a moderate form, and in 
52.3% with a severe form. The study concluded that reassur-
ance should be the first-line treatment for women with mas-
talgia and pharmacological management should be reserved 
only in the cases refractory to this form of management.
Vaidyanathan et al. stressed the need for education and 
regulation of continuous professional development for phy-
sicians so that they can distinguish benign breast conditions 
from malignant ones and know when to reassure or refer pa-
tients to specialists for evaluation.42
Physical measures 
Improved external mechanical support has been found to re-
lieve breast pain, and many studies have been conducted on 
the therapeutic value of a supporting brassiere in mastalgia. 
Be-Lieu found that about 70% of women wear an improper-
ly fitted brassiere.43 Symptomatic women may benefit from 
advice regarding proper selection and fitting of a brassiere, 
with recommendations for wearing a soft, supportive bras-
siere during sleep and use of a sports bra during exercise.44 
Wilson and Sellwood conducted an interventional study that 
enrolled 114 women whose mastalgia lasted more than 7 
days in each menstrual cycle, interfering with daily life or 
sleep, and severe enough to require treatment.45 Subjects 
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were provided with 2 properly fitting brassieres and coun-
selled about the correct technique for wearing a brassiere by 
a trained nurse and monitored at 3-month intervals for up 
to 18 months. One hundred of the subjects completed fol-
low-up, and 26 of them experienced complete relief, 49 ex-
perienced an improvement in pain, 21 had neither improved 
nor worsened pain, and 4 experienced worsened pain. Fur-
thermore, 11 of 15 patients who had required medication 
for breast pain experienced improvement or relief with this 
intervention.
Exercise
Exercise has been found to have a positive impact in the al-
leviation of symptoms in many severe cases of chronic pain, 
fibromyalgia, and chronic fatigue syndrome. Genc et al. un-
dertook a randomized controlled trial to study the impact 
of exercise on mastalgia. Mastalgia patients were randomly 
assigned to a control group and an exercise group. The use of 
a sports brassiere, abstention from food containing caffeine 
and methylxanthines, and simple analgesics were recom-
mended for both groups, and an exercise programme inter-
vention was added for the exercise group. The exercises were 
conducted 3 times per week for 6 weeks. Participants were 
evaluated for breast pain before and 6 weeks after the study. 
Serum cytokine levels were also collected and analysed. The 
study concluded that the exercise treatment is beneficial for 
patients with mastalgia and that it can be suggested by cli-
nicians.46
Diet and nutritional intervention
A low-fat, high-carbohydrate diet and weight reduction have 
been proven to result in a reduction in hormones, such as 
prolactin, and relieve the intensity of breast pain.22,47
In a single-blind, randomized, controlled study, Boyd et 
al. assessed the effect of a low-fat diet (15% energy from fat) 
on severe cyclic mastalgia and found that reduced swelling, 
tenderness, and nodularity were reported in 60% of patients 
in the intervention group.48
The role of dietary modification in the form of caffeine 
restriction is still controversial as mentioned above in the 
section on aetiology. While Minton and Abou-Issa exam-
ined cases of fibrocystic disease and found that caffeine re-
striction produced significant symptomatic improvement in 
many women, Millet and Dirbas21 and Anjum et al.49 found 
no significant relationship between breast pain with caffeine 
intake. 
Relaxation therapy
Given the involvement of psychological elements in the ae-
tiology of mastalgia, relaxation therapy (RT) has been pro-
posed as a treatment for breast pain. Fox et al. recruited 45 
women with mastalgia severe enough to warrant evaluation 
and treatment to a randomized clinical trial of daily pain dia-
ry keeping and RT versus diary keeping on its own (control). 
The study lasted for 12 weeks; women assigned to RT prac-
tised daily with an audio cassette recording during weeks 
5–8. Women who received RT showed significant improve-
ment, compared to the control group, as assessed by the Car-
diff Breast Scale (P = 0.05). The study suggested that RT may 
be more effective for cyclic than noncyclic mastalgia.50
Evening primrose oil
The role of EPO in the management of mastalgia is contro-
versial. As mentioned above in the aetiology, breast tissue 
is abnormally sensitive to normal oestrogen levels due to 
the relative deficiency of GLA. With prolonged high-dose 
treatment (320 mg/day for 3 to 6 months), the GLA content 
of EPO has been found to restore the balance of fatty acids 
in the breast tissue, with high efficacy and minimal side ef-
fects.23,51
However, many other studies including certain random-
ized, placebo-controlled, double-blind clinical trials have 
found EPO to have no efficacy in the treatment of cyclic 
mastalgia.52–54 
Trials have been conducted in which EPO was admin-
istered along with some other elements with equivocal re-
sults. Pruthi et al. conducted a double-blind, randomized, 
placebo-controlled trial at 2 academic medical centres in the 
United States to evaluate the effectiveness of vitamin E, EPO, 
and a combination of vitamin E and EPO for pain control 
in women with cyclic mastalgia. They concluded that daily 
doses of 1200 IU vitamin E, or 3000 mg EPO, or a combina-
tion of these same doses of vitamin E and EPO, taken for 6 
months, may decrease the severity of cyclic mastalgia.55
Blommers et al. conducted a randomized, double-blind, 
factorial clinical trial to evaluate the effect of EPO and fish oil 
on breast pain in premenopausal women with severe chronic 
mastalgia.56 They placed 120 women randomly into 4 groups 
and orally administered (a) fish oil and control oil, (b) eve-
ning primrose oil and control oil, (c) fish oil and evening 
primrose oil, or (d) both control oils. Corn oil and corn oil 
with wheat germ oil were used as control oils. The change 
in the percentage of days with breast pain after 6 months of 
treatment was analysed on an intention-to-treat basis, and 
it was concluded that all the groups showed a decrease in 
pain and neither EPO nor fish oil offered a clear benefit over 
control oils in the treatment of mastalgia.
Phytoestrogens
Phytoestrogens or dietary oestrogens are plant-derived 
xenoestrogens not generated within the endocrine system 
but consumed by eating phytoestrogenic plants. They are 
a diverse group of naturally occurring nonsteroidal plant 
compounds that, because of their structural similarity with 
oestradiol (17β-oestradiol), can cause oestrogenic or an-
ti-oestrogenic effects. In this category, studies have been 
conducted on 2 sources, as described below:
Isoflavones 
Ingram et al. conducted a small, double-blind, randomized, 
controlled trial to study the roles of isoflavones in the treat-
ment of cyclical breast pain.57 A total of 18 women were ran-
domized to receive a placebo or 40 mg isoflavones or 80 mg 
isoflavones. It demonstrated that isoflavones led to a signifi-
cant reduction in cyclic mastalgia (13% for placebo, 44% for 
40 mg of isoflavones per day, and 31% for 80 mg per day).
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Flaxseed
Goss et al. examined the effects of dietary flaxseed in women 
with severe cyclic mastalgia.58 A total of 116 women were en-
rolled in the double-blind, placebo-controlled trial with the 
treatment group receiving 25 g of flaxseed daily, in a muffin, 
and monitored for up to 4 menstrual cycles. Breast pain was 
alleviated in both treatment groups but was reduced to a sig-
nificantly higher degree in the flaxseed group.
Topical Nigella sativa seed oil
Huseini et al. conducted a randomized, triple-blind, active, 
and placebo-controlled clinical trial to study the effective-
ness of topical Nigella sativa seed oil in the treatment of mas-
talgia.59 Standardized N. sativa seed oil (600 mg) was applied 
to the site of pain twice daily for 2 months in 52 women, and 
the impact on pain was compared—using a visual analogue 
scale—to that of topical diclofenac (20 mg twice daily in 51 
women) and placebo (n = 53). The study found that the pain 
scores of the active treatment groups at 1 and 2 months were 
significantly lower than those of the placebo group (both 
P < 0.001) and the pain scores of the placebo group at 1 and 
2 months were not significantly different from the baseline 
(P>0.05). No adverse effects were observed. It was concluded 
that the topical N. sativa seed oil is safe, more effective than 
placebo, and has a clinical effectiveness comparable to topi-
cal diclofenac in the treatment of cyclic mastalgia.
Vitex agnus-castus (Chaste tree) berry extract
Vitex agnus-castus L., commonly known as Agnus Castus or 
the Chaste tree, is a deciduous shrub native to Mediterranean 
Europe and Central Asia. It is postulated that V. agnus-castus 
fruit extract suppresses stress-induced latent hyperprolac-
tinaemia by blocking the dopamine-2 receptor type on the 
pituitary gland, thereby relieving cyclic mastalgia. The ad-
verse events following V. agnus-castus treatment have been 
found to be mild and reversible. Carmichael studied the data 
from randomized and nonrandomized studies regarding the 
efficacy and safety of V. agnus-castus in a systematic fashion 
and concluded that V. agnus-castus can be considered an ef-
fective alternative phytotherapeutic agent in the treatment of 
mastalgia.60
Halaska et al. conducted a placebo-controlled, random-
ized, double-blind study and investigated the efficacy of a V. 
agnus castus extract-containing solution (VACS) in patients 
suffering from cyclic mastalgia, and found VACS to be effec-
tive and well tolerated.61
Low-intensity laser therapy 
Low-intensity laser therapy (LILT) has been recently pro-
posed as a tool for the management of mastalgia. Saied et al. 
conducted a double-blind study on 80 patients with cyclic 
mastalgia after randomly dividing them into 2 groups (A and 
B). In group A, patients were treated with bromocriptine and 
EPO; in group B, LILT was applied with specified dosimetry, 
using a device that delivers He-Ne laser combined with 4 in-
frared diode lasers. Evaluation of treatment was both subjec-
tive (using a visual analogue scale) and objective (studying 
the degree of drop in plasma cortisol levels). A good response 
was observed in the laser group (82.5%) compared to 63.9% 
in the bromocriptine/EPO group. There was a significant im-
provement in pain in both the groups (P < 0.05), but pain was 
alleviated in a broader range of patients in the LILT group.62
Pharmacologic interventions
Progesterone
McFadyen et al. found that progesterone cream applied lo-
cally was no better than placebo cream in relieving mastal-
gia.63 Along similar lines, a small, randomized, double-blind 
crossover study (N = 26) by Maddox et al. concluded that the 
therapeutic response of 20 mg/day of oral medroxyproges-
terone acetate during the luteal phase was no better than a 
placebo in the management of cyclic mastalgia.64 However, 
in a randomized, double-blind, placebo-controlled study 
conducted in Italy by Nappi et al., a vaginal cream of mi-
cronized progesterone was found to be effective in reducing 
pain in 64.9% of cases, compared with 22.2% of controls.65
Ormeloxifene (centchroman)
Ormeloxifene, also known as centchroman, is a selective 
oestrogen receptor modulator (SERM). It is best known as a 
nonhormonal, nonsteroidal oral contraceptive that is taken 
once per week. Rathi et al. conducted a prospective, open-la-
bel, single-arm study using the pretest–posttest design.66 A 
total of 100 women suffering from moderate to severe mas-
talgia were enrolled and received 30 mg/day of centchroman 
for 12 weeks followed by observation for 12 weeks. Complete 
response was observed in 66% of cyclic mastalgia and 40% 
of noncyclic mastalgia patients after 1 week of therapy, and 
the improvements continued over time in both groups and 
at completion of treatment (12 weeks) 92% of patients in 
the cyclic group and 80% of patients in the noncyclic group 
were pain free. The positive impact of the drug persisted at 
24 weeks (P = 0.001). The study found centchroman to be ef-
fective in treating mastalgia, and the authors recommend its 
use as a first-line drug.
Dhar and Srivastava conducted a similar study on 60 
mastalgia patients and recorded a decrease in visual analogue 
scale scoring from 10 to 3 in 90% of the patients at the end 
of the first week, and almost all of the patients were painless 
at the end of 1 month.67 Tejwani et al. conducted a random-
ized, controlled trial of centchroman versus danazol, in the 
management of mastalgia, involving 81 patients.68 Of these 
81 patients, 39 were randomized to the danazol arm and 42 
to the centchroman arm. Treatment was given for 12 weeks, 
followed by an observation period of 12 weeks. A reduction 
in pain score to ≤ 3 was achieved by 89.7% of women in the 
centchroman group (P = 0.001) at 12 weeks and 69.44% of 
women in the danazol group (P = 0.001). Three months after 
stopping therapy, centchroman was more effective than da-
nazol in terms of pain reduction at 24 weeks (P = 0.019). The 
study concluded that centchroman is an effective, safe and 
inexpensive treatment for mastalgia.
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Toremifene
Toremifene citrate is an oral SERM that predominantly has 
anti-oestrogenic properties with minimal oestrogenic activ-
ity. Hamed et al. investigated this drug in the treatment of 
mastalgia and evaluated its tolerability and efficacy by en-
rolling 17 premenopausal women, with a mean age of 37.7 
years, complaining of moderate to severe mastalgia (70% of 
patients with cyclic and 30% with noncyclic mastalgia).69 A 
dose of 60 mg toremifene was administered daily. The pro-
posed treatment period was to be 12 weeks, but 4 patients 
(23.5%) withdrew from the study after 4 weeks because of 
side effects. All women with cyclic mastalgia responded to 
toremifene, compared with only 75% of those with noncyclic 
mastalgia. This study concluded that toremifene is an effec-
tive agent in the treatment of mastalgia, but a high incidence 
of side effects makes it ineligible as an agent of choice.
On the other hand, Gong et al., after a double-blind, ran-
domized controlled trial, concluded that toremifene is a fea-
sible therapy for moderate and severe mastalgia, especially 
cyclic mastalgia with tolerable adverse effects.70
Topical nonsteroidal anti-inflammatory drugs
Many studies have found that topical nonsteroidal anti-in-
flammatory drugs (NSAIDs) are effective in relieving breast 
pain, and these may be considered as a first-line treatment, 
as the benefits are thought to outweigh the risk of adverse 
effects. Irving and Morrison, in their prospective pilot study, 
demonstrated the potential for effective treatment of cy-
clic and noncyclic mastalgia using stronger types of topical 
NSAIDs—diclofenac and piroxicam.71 Colak et al. conduct-
ed a prospective, randomized, blinded, placebo-controlled 
study (N = 108) and demonstrated a significant improvement 
with topical diclofenac diethylammonium (Emulgel) in the 
treatment group, for both cyclic and noncyclic mastalgia, 
with minimal side effects after application for 6 months.72 
The authors proposed the topical gel as a reasonable alterna-
tive to a systemic analgesic.
Danazol
Danazol is a synthetic testosterone that binds to progesterone 
and androgen receptors, although the precise mechanism of 
action in the treatment of mastalgia is unknown. Multiple 
studies conducted over the last 4 decades have proven the 
benefits of 200 mg of danazol per day. Mansel et al. compared 
danazol 200 mg/day with a placebo in 28 women with cyclic 
mastalgia, with crossover at 3 months, and mean pain scores 
showed a significant response to danazol.73 Ortiz-Mendoza 
and Olvera-Mancilla achieved control of moderate to severe, 
cyclic and noncyclic mastalgia in about 80% of patients, 
though adverse effects were documented in 20.6% of cases.74
The drawback with the use of danazol is the appearance 
of adverse effects in more than 50% of patients; these include 
weight gain, hirsutism, menstrual irregularity (amenorrhoea 
or menorrhagia), deepening of the voice, and hot flushes. 
Studies have been conducted on lower doses of danazol to 
investigate options that minimize adverse effects. Further-
more, there is a possibility of recurrence in up to 50% of 
patients on discontinuation of treatment. O’Brien and Abu 
Khalil evaluated the efficacy and side effects of danazol 
200mg /day, with administration limited to only during the 
luteal phase of the menstrual cycle, and demonstrated effec-
tive relief of cyclic mastalgia and minimal side effects.75
Maddox et al.76 and Harrison et al.77 also conducted 
studies on the impact of low doses of danazol administered 
during the luteal phase and concluded that a low-dose regi-
men may be suitable for women with chronic, relapsing cy-
clic mastalgia or those who develop side effects on standard 
doses.
Tamoxifen 
Tamoxifen is an effective treatment to control moderate to 
severe mastalgia and, like danazol, can be prescribed when 
first-line treatments are ineffective. Multiple studies have 
proven its effectiveness. In a study conducted by Ortiz-Men-
doza et al., involving 141 cases, tamoxifen achieved pain con-
trol in 67% of patients, and 64 patients (45%) showed side 
effects (9.7% with 10 mg and 41.6% with 20 mg; P < 0.001), 
with dizziness and headache being the most frequent and 
significant side effects.78 Only 8 patients (5.6%) stopped 
treatment. In a double-blind, randomized, controlled trial, 
Fentiman et al. observed significant pain relief in 75% of pa-
tients treated with tamoxifen 20mg/day over 3 months.79 The 
most frequent side effects were hot flushes (27%) and vaginal 
discharge (17%).
Kontostolis et al. compared the benefits and side effects 
of tamoxifen versus danazol in women with severe cyclic 
mastalgia and found tamoxifen to be highly efficacious and 
more cost-effective.80 Jain et al. compared the outcomes of 
tamoxifen therapy with centchroman (ormeloxifene) and 
found the 2 to be of similar effectiveness in providing pain 
relief for mastalgia.81
Bromocriptine
Bromocriptine is a dopamine agonist that stimulates the 
dopaminergic receptors in the anterior pituitary, thereby 
blocking the release of prolactin. It is administered at an oral 
dose of 2.5 mg twice daily. In a meta-analysis conducted by 
Srivastava et al., bromocriptine was found to offer a reduc-
tion in the weighted mean pain score equal to −16.31 (95% 
confidence interval [CI] = −26.35 to −6.27).82
In a randomized, controlled, multicentre trial of 3 and 
6 months of treatment, Mansel and Dogliotti found bro-
mocriptine to be effective; however, adverse effects, includ-
ing headaches and dizziness, resulted in a high dropout rate 
in this study.83 Similarly, in a study by Nazli et al., bromocrip-
tine was found to produce complete relief of symptoms in 
65% of cases, but side effects were experienced by 40% of 
subjects.84 Due to the high incidence of adverse effects, bro-
mocriptine is reserved for exceptional cases where other 
measures do not work or are contraindicated.
Surgical intervention
Surgical interventions have a limited role in the manage-
ment of mastalgia and data about this option are sparse in 
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the literature. Davies et al., after a retrospective study con-
ducted at the University Hospital of Wales, Cardiff, conclud-
ed that surgery for mastalgia should be considered only for 
a minority of women who are resistant to all other forms of 
treatment. The authors stressed that, before any surgical pro-
cedure, patients must be informed of possible complications 
inherent in reconstructive surgery and warned that in 50% 
of cases their pain will not improve.85 Steinbrunn et al. pro-
posed that surgery can be useful for selected patients with a 
discrete, small trigger spot when the symptoms may be re-
lieved by excision of that spot.86
Long-term course of mastalgia
The course of mastalgia is generally long. Davies et al. 
found that the median age of onset of breast pain was 36 
years (range 12–63 years).87 The median duration of pain was 
found to be 12 years. Pain persisted in 68 cyclic mastalgia 
patients (57%) and 35 noncyclic mastalgia patients (64%). 
In cyclic mastalgia, pain resolution was commonly associ-
ated with a “hormonal event”, notably menopause; in non-
cyclic mastalgia, it more often occurred spontaneously. The 
authors found that severe mastalgia runs a chronic relapsing 
course and often requires repeated drug treatments.
Conclusions
Mastalgia is a common symptom that causes anxiety 
among women and burdens healthcare facilities. The precise 
aetiology is unknown, but a broad classification divides mas-
talgia into cyclic and noncyclic forms. Careful evaluation to 
rule out breast cancer and reassure the patient is enough to 
relieve pain in many cases. In some patients, however, mas-
talgia is severe enough to require further evaluation and 
treatment. Beyond reassurance, the management options 
can be nonpharmacologic or pharmacologic. Surgical inter-
ventions have virtually no role in management.
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